研究者
J-GLOBAL ID：202001006127789848
更新日: 2024年01月30日
杉村 直美
スギムラ ナオミ | SUGIMURA NAOMI
所属機関・部署：
職名：
病院助教
競争的資金等の研究課題 (1件)：
- 2022 - 2025 ウイルス療法を基軸とした大腸癌に対する複合がん免疫療法の開発
論文 (5件)：
-
Takaya Shimura, Naomi Sugimura, Hiroyasu Iwasaki, Takahito Katano, Hiromi Kataoka. Successful diagnosis and endoscopic submucosal dissection of a gastric gastrointestinal stromal tumor originating from the submucosal layer. VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy. 2022. 7. 2. 65-67
-
Naomi Sugimura, Tsutomu Mizoshita, Tomoya Sugiyama, Shozo Togawa, Tomokatsu Miyaki, Taketo Suzuki, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2019. 51. 7. 967-971
-
Taketo Suzuki, Tsutomu Mizoshita, Satoshi Tanida, Naomi Sugimura, Takahito Katano, Hirotada Nishie, Hiromi Kataoka. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor. JGH open : an open access journal of gastroenterology and hepatology. 2019. 3. 3. 217-223
-
Suzuki T, Mizoshita T, Sugiyama T, Hirata Y, Kimura Y, Suzuki Y, Yamada T, Tsukamoto H, Mizushima T, Sugimura N, et al. Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case reports in gastroenterology. 2019. 13. 1. 37-49
-
Tsutomu Mizoshita, Takahito Katano, Satoshi Tanida, Atsuyuki Hirano, Tomokatsu Miyaki, Keiji Ozeki, Yuka Suzuki, Naomi Sugimura, Hiromi Kataoka, Takashi Joh. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine. 2017. 96. 32. e7800
学位 (1件)：
前のページに戻る
